Multiply resistant enterococci have emerged as increasingly important nosocomial pathogens during the last decade (10, 12, 13) . This has increased the interest in searching for new antibiotics or modifications of older antibiotics with activity against multiply resistant staphylococci and enterococci. One of these agents is evernimicin (SCH 27899) (Ziracin), an oligosaccharide antimicrobial agent belonging to the everninomicins that has been developed by Schering-Plough. This compound has shown excellent activity against enterococci, staphylococci, and streptococci of human origin (5, 6, 8, 11, 14) but was recently suspended by the company from any further clinical development. The everninomicins have been known since the 1960s (15) but have not previously gained any clinical interest.
Another oligosaccharide, avilamycin, has been used as a growth promoter for food animals in the European Union for several years, and resistance to avilamycin has frequently been found among Enterococcus faecium isolates from broilers in Denmark (2) . Cross-resistance between avilamycin and evernimicin has been detected among Enterococcus faecalis and E. faecium isolates (1) .
The mode of action of avilamycin and evernimicin is not well elucidated. It has been suggested that avilamycin acts by binding to the 30S part of the ribosome and thereby inhibiting the protein synthesis (16) . However, recently Adrian and Klugman reported that single base-pair mutations in ribosomal protein L16 giving rise to an amino acid substitution (Ile-52 3 Ser-52 or Thr-52) resulted in decreased susceptibility to evernimicin in Streptococcus pneumoniae (P. V. Adrian and K. P. Klugman, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. C110, 1998). Furthermore, McNicholas et al. (7) showed that evernimicin binds the 50S subunit and that the binding sites for avilamycin and evernimicin overlap on the 50S subunit.
This study was conducted to assess the effects of variations in the L16 sequence of E. faecalis and E. faecium isolates on susceptibility to the oligosaccharide antimicrobial agents avilamycin and evernimicin (SCH27899).
Bacterial isolates. The bacterial isolates chosen for sequence analysis of L16 are shown in Table 1 . The isolates were chosen on the basis of their susceptibility or resistance to avilamycin. Eleven avilamycin-resistant and 4 susceptible isolates of E. faecalis and 11 resistant and 6 susceptible E. faecium isolates were chosen. All isolates originated from different broiler farms or pig herds and were collected from the continuous surveillance of antimicrobial resistance among food animals in Denmark between 1995 and 1998 (2). The following reference strains were included: E. faecalis ATCC 19433, E. faecalis ATCC 29212, and E. faecium CCUG542.
Susceptibility testing. Susceptibility to avilamycin was determined by culturing on Mueller-Hinton II agar plates containing twofold serial dilutions of antimicrobials (MIC determinations) at dilutions ranging from 0.25 to 128 g/ml, according to NCCLS guidelines (9) . The susceptibility to evernimicin (SCH27899) was determined by using the E-test according to the manufacturer's guidelines (AB Biodisk, Solna, Sweden).
PCR amplification and DNA sequencing. The sequence for L16 for Bacillus subtilis (accession number U43929) and S. pneumoniae (accession number AF126059) was retrieved from GenBank. The sequence from B. subtilis was used to search the database of The Institute for Genomic Research [TIGR] (http://www.tigr.org/cgi-bin/BlastSearch/blast.cgi?) for similar sequences for E. faecalis. Similarly, L16 sequences of Staphylococcus aureus, Streptococcus mutans, and Streptococcus pyogenes were also retrieved from the TIGR database. Based on a similar sequence of E. faecalis (V583), fragments (414 internal base pairs) of the L16 gene were amplified using the primers P1 (5Ј-AAACGTGTAAAACACCGTCG-3Ј) and P2 (5ЈCATTCGATTCACCACCCATT-3Ј) (Fig. 1) . The amplification products were sequenced on an ABI 373A automatic sequencer using the AmpliTaq FS dye terminator kit (Applied Biosystems, Foster City, Calif.). The sequences were compared and analyzed using DNAsis software (Hitachi Software Engineering Co., Ltd.).
PFGE.
Pulsed-field gel electrophoresis (PFGE) analysis of the 22 avilamycin-resistant E. faecalis and E. faecium isolates chosen for sequence analysis was performed as previously described (4) .
Complete agreement between resistance and susceptibility to avilamycin and evernimicin (SCH27899) was found among the isolates. The MICs of avilamycin were between 0.5 and 2 g/ml for the susceptible isolates and from 32 to Ͼ64 g/ml for the resistant isolates (Table 1) . For evernimicin (SCH27899) the MICs ranged from 0.125 to 0.75 g/ml for the avilamycinsusceptible isolates and from 2 to 8 g/ml for the avilamycinresistant isolates. All oligosaccharide-susceptible E. faecalis isolates had a DNA sequence identical to the sequence retrieved from the TIGR database. The E. faecium type strain CCUG542 and the five oligosaccharide-susceptible E. faecium isolates all shared the same DNA sequence. This sequence showed 89% DNA homology and 95% amino acid homology to the sequence of E. faecalis.
Two different mutations associated with decreased susceptibility to evernimicin have previously been observed among S. pneumoniae isolates (Adrian and Klugman, 38th ICAAC). These mutations, ATC (Ile-52) 3 AGC (Ser-52) and ATC (Ile-52) 3 ACC (Thr-52), were detected among 1 and 5, respectively, of the 11 E. faecium isolates examined in this study (Table 1 and Fig. 1 ). In addition, another mutation [CGT (Arg-56) 3 CAT (His-56)] was detected in all the 11 resistant E. faecalis isolates and in the remaining 5 resistant E. faecium isolates.
All resistant E. faecium isolates were of different genotypes as determined by PFGE typing. This indicates that resistance has developed among several different clones. In contrast, all E. faecalis isolates belonged to the same indistinguishable SmaI PFGE type, even though all the isolates were from different herds and collected during a period of 3 years.
When the DNA sequence and translated amino acid sequence of the L16 gene were compared to those of B. subtilis, E. faecalis, S. aureus, S. pneumoniae, and S. pyogenes, it was observed that all three mutations were within an otherwise conserved 21-amino-acid area of L16. The observed conservation of this area in several bacterial species could indicate that this region is essential for the function of L16 in gram-positive bacteria. The conservation in amino acid sequence could perhaps indicate that oligosaccharide-resistant variants with changes in this region are less fit than the susceptible variants and that resistance thus will disappear over time.
Recently, a decrease in the occurrence of avilamycin-resistant E. faecium isolates has been detected along with a decreased consumption (3), indicating that resistance will decrease when the selective pressure is removed.
In conclusion, the observations in this study and the studies by Adrian and Klugman (38th ICAAC) and McNicholas et al. Nucleotide sequence accession numbers. The sequences obtained in this study have been deposited in GenBank under the accession numbers AF291861, AF291862, AF291863, AF291864, and AF291865.
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